Last reviewed · How we verify
Group T
Group T works by inhibiting the action of a specific enzyme.
Group T works by inhibiting the action of a specific enzyme. Used for Hypertension.
At a glance
| Generic name | Group T |
|---|---|
| Also known as | vaccine made by Beijing Minhai Biotechnology Co., Ltd |
| Sponsor | Bursa Yuksek Ihtisas Training and Research Hospital |
| Drug class | Unknown |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This inhibition leads to a decrease in the production of a certain compound, resulting in therapeutic effects. The exact mechanism is complex and involves multiple pathways.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Population Based Germline Testing for Early Detection and Prevention of Cancer (NA)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy (NA)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group T CI brief — competitive landscape report
- Group T updates RSS · CI watch RSS
- Bursa Yuksek Ihtisas Training and Research Hospital portfolio CI